Osage University Partners has contributed to a series A round for Vor Biopharma, an oncology drug developer based on work by Siddhartha Mukherjee at Columbia University.

Vor Biopharma, a US-based cancer treatment developer based on research at Columbia University, closed a $42m series A round on Thursday that included spinout-focused investment firm Osage University Partners.
Venture capital firm 5AM Ventures and investment firm RA Capital Management co-led the round, which also featured pharmaceutical companies PureTech Health and Novartis, as well as medical product group Johnson & Johnson.
Johnson & Johnson and Novartis invested through subsidiaries Johnson & Johnson Innovation – JJDC and Novartis Institutes of…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?